Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Imaging for staging bladder cancer: a clinical study of (111)indium-labelled anti-MUC1 mucin intravenous monoclonal antibody C595
Autore:
Hughes, ODM; Perkins, AC; Frier, M; Wastie, ML; Denton, G; Price, MR; Denley, H; Bishop, MC;
Indirizzi:
City Hosp, Dept Urol, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB t Urol, Nottingham NG5 1PB, England City Hosp, Dept Pathol, Nottingham NG5 1PB, England City Hosp NottinghamEngland NG5 1PB Pathol, Nottingham NG5 1PB, England Univ Nottingham, Sch Pharmaceut Sci, Dept Med Phys, Nottingham NG7 2RD, England Univ Nottingham Nottingham England NG7 2RD , Nottingham NG7 2RD, England Univ Nottingham, Sch Pharmaceut Sci, Canc Res Lab, Nottingham NG7 2RD, England Univ Nottingham Nottingham England NG7 2RD , Nottingham NG7 2RD, England
Titolo Testata:
BJU INTERNATIONAL
fascicolo: 1, volume: 87, anno: 2001,
pagine: 39 - 46
SICI:
1464-4096(200101)87:1<39:IFSBCA>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
CARCINOMAS; RADIOIMMUNOSCINTIGRAPHY; TOMOGRAPHY; TUMORS;
Keywords:
bladder cancer; staging; monoclonal antibody; MUC1 mucin; radio-immunoscintigraphy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Bishop, MC City Hosp, Dept Urol, Hucknall Rd, Nottingham NG5 1PB, England City Hosp Hucknall Rd Nottingham England NG5 1PB 1PB, England
Citazione:
O.D.M. Hughes et al., "Imaging for staging bladder cancer: a clinical study of (111)indium-labelled anti-MUC1 mucin intravenous monoclonal antibody C595", BJU INT, 87(1), 2001, pp. 39-46

Abstract

Objective To investigate the clinical application of an In-111-labelled anti-MUC1 mucin monoclonal antibody (mAb) imaging for staging invasive bladder cancer. Patients and methods Indirect immunohistochemistry was used to confirm theexpression of the MUC1 target antigen by metastatic tumours, Twelve patients with bladder cancer (two with superficial and 10 with locally invasive/metastatic disease) underwent planar gamma -scintigraphy 48 h after an intravenous injection with In-111-labelled anti-MUC1 mucin mAb C595,Results No bladder uptake was detected in the two patients with superficial disease, but scintigraphy showed primary and recurrent bladder tumours and metastases in nine of the remaining 10 patients with invasive disease. Inthree patients additional staging information was obtained from the mAb imaging which would have altered patient management, There were no reported side-effects,Conclusion This study confirmed the ability of the mAb technique to detectboth primary and recurrent invasive bladder tumours and distant metastases. Some lesions shown by mAb imaging were not detected by other methods. Theuse of mAb imaging has the potential to improve clinical staging and assist in selecting those patients most likely to benefit from radical therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 23:01:34